FSD Pharma Inc.

HUGE

CA35954B4047

Biotechnology & Medical Research

Delayed Canadian Securities Exchange Other stock markets 11:56:25 2024-04-29 am EDT			5-day change	1st Jan Change
0.62 ^CAD	-6.06%		-3.12%	-48.33%

Apr. 25	FSD Pharma Says Celly Nutrition Partners with Six+One for US Launch of Dietary Supplement	MT
Apr. 08	FSD Pharma Receives Nasdaq Non-Compliance Notice	MT

FSD Pharma Inc. announced that it has received CAD 0.000046 million in funding

December 04, 2023

On December 5, 2023, FSD Pharma Inc closed the transaction. The transaction included participation from new investor Xorax Family Trust for 12 Class A shares for gross proceeds of CAD 22.80.

Latest news about FSD Pharma Inc.

FSD Pharma Says Celly Nutrition Partners with Six+One for US Launch of Dietary Supplement	Apr. 25	MT
FSD Pharma Receives Nasdaq Non-Compliance Notice	Apr. 08	MT
FSD Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
FSD Pharma Edging Up In US Premarket Trade As Signs Agreement With iNGENu CRO	Mar. 27	MT
FSD Pharma Brief: Signed Agreement With iNGENu CRO To Conduct a Clinical Study To Assess Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults	Mar. 27	MT
FSD Pharma Brief: Submitting a Phase-1b Clinical Trial Application for its Proprietary Beverage unbuzzd	Mar. 11	MT
FSD Pharma Inc. Submits A Phase-1B Clinical Trial Application for Ethics Committee for Its Proprietary Beverage Unbuzzd	Mar. 11	CI
FSD Pharma Presents "Positive" Phase 1 Lucid-21-302 Results at ACTRIMS Forum	Mar. 05	MT
Refile-- FSD Pharma Brief: Presenting "Positive" Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum	Mar. 05	MT
FSD Pharma Brief: Presenting "Positive: Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum	Mar. 05	MT
FSD Pharma Inc. Presents Positive Results on First-In-Human Phase-1 Study of Lucid-21-302 (Lucid-Ms) At Americas Committee for Treatment and Research in Multiple Sclerosis 2024 Forum	Mar. 05	CI
MT Newswires Canada Stocks To Watch: SSR Mining, Tricon Residential; Imperial Oil; FSD Pharma	Feb. 19	MT
Reflile: FSD Pharma Up 3.7% In US Premarket As Says Court of Appeal Dismissed Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Near $3 Million	Feb. 06	MT
FSD Pharma Up 3.7$ In US Premarket As Says Court of Appeal Dismissed Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Near $3 Million	Feb. 06	MT
FSD Pharma Brief: Says Court of Appeal Dismissed Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Approximately $3 Million	Feb. 06	MT
FSD Pharma Inc. Announces Board Changes	Jan. 29	CI
FSD Pharma Files Final Base Shelf Prospectus to Replace Expired Base Shelf Prospectus	Dec. 27	MT
FSD Pharma Inc. announced that it has received CAD 0.000046 million in funding	Dec. 04	CI
FSD Pharma Inc. completed the Spin-Off of Celly Nutrition Corp.	Nov. 28	CI
FSD Pharma Inc. announced that it expects to receive CAD 0.000046 million in funding	Nov. 26	CI
FSD Pharma Inc. Announces Change of CEO	Nov. 16	CI
FSD Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
FSD Pharma Enters Agreement on Distribution of Portion of Celly Nutrition Shareholdings	23-10-05	MT
FSD Pharma Inc. agreed to Spin-Off 34.66% stake of Celly Nutrition Corp.	23-10-03	CI
FSD Pharma Shares Rise After Saying Interim Report Shows Multiple Sclerosis Treatment Candidate Safe, Well-Tolerated	23-09-18	MT

FSD Pharma Inc. is a Canada-based biotechnology company. The Company operates through two segments: Biotechnology and Strategic Investments. Its Biotechnology segment is focused on furthering the research and development of the Companyâs two primary drug candidates consisting of Lucid-MS and Lucid-PSYCH, as well as the development of UNBUZZD. The Companyâs Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial real estate property. Lucid-PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. UNBUZZD is a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of potentially quickly relieving from the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle.

Sector

Biotechnology & Medical Research

Calendar

2024-05-09 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
FSD PHARMA INC.	-48.33%	19.34M
VERTEX PHARMACEUTICALS INCORPORATED	-2.66%	103B
REGENERON PHARMACEUTICALS, INC.	+1.89%	95.28B
ARGENX SE	+1.46%	22.15B
BIONTECH SE	-15.71%	21.02B
GENMAB A/S	-8.58%	18.15B
WUXI APPTEC CO., LTD.	-38.74%	16.73B
BEIGENE, LTD.	-13.32%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+4.68%	13.68B
SAREPTA THERAPEUTICS, INC.	+35.33%	12.17B